Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype

7 Nov 2024

Abstract excerpt

BACKGROUND: Clinical trials and real-world experience have provided evidence for the clinical benefits of mepolizumab, an anti-IL-5 biologic, in severe asthma. However, limited data exist regarding the impact of mepolizumab on airway remodeling. OBJECTIVE: We sought to investigate the effect of mepolizumab on airway structural remodeling in patients treated for severe asthma in routine clinical care. METHODS: The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asthma and respiratory diseases
Share to Chronic Obstructive Pulmonary Disease (COPD) Research
Share to Delphi Technique in Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39521278
DOI: 10.1016/j.jaci.2024.10.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotypePMID 39521278Read ↗

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic PhenotypeSemantic proximity Read ↗

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotypeSemantic proximity Read ↗

Clinical characteristics and biological treatment responses of patients with late-onset asthma phenotype.Semantic proximity Read ↗

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read ↗

The effect of biologics on lung function improvements among severe eosinophilic asthma patients with partial reversibility or fixed obstructive defects: A retrospective analysisSemantic proximity Read ↗

The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic AsthmaSemantic proximity Read ↗

Effect of the Arg16Gly β2-Adrenergic Receptor Polymorphism on Long-Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype-Stratified, Multicenter Study.Semantic proximity Read ↗

Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives.Semantic proximity Read ↗

Noneosinophilic asthma in children: relation with airway remodelling.Semantic proximity Read ↗

Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.Semantic proximity Read ↗

Reslizumab in the treatment of severe eosinophilic asthma: an update.Semantic proximity Read ↗

Reslizumab and Eosinophilic Asthma: One Step Closer to Phenotype-directed Therapy?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.